

ForPatients

by Roche

Macular Degeneration Age-Related Macular Degeneration Geographic Atrophy

Testing a new medicine (galegenimab) to find out if it is effective for a type of eye disease (geographic atrophy secondary to age-related macular degeneration)

A Study Assessing the Safety, Tolerability, and Efficacy of RO7171009 in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

Trial Status
Terminated

Trial Runs In
1 Countries

Trial Identifier
NCT03972709 GR40973

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This clinical trial was done to find out if a new medicine called, “galegenimab,” was effective for the treatment of patients with a type of eye disease (geographic atrophy [GA] secondary to age-related macular degeneration [AMD]). This was a phase 2, randomized, sham-controlled study to assess the efficacy, safety, and tolerability of eye injections (intravitreal injections) given to patients with GA secondary to AMD. The study took place at 77 study centers at 71 study sites in one country – the USA.

Genentech, Inc. (A part of F. Hoffmann-La Roche Ltd., Switzerland) Sponsor	Phase 2 Phase
--	-------------------------

NCT03972709 GR40973
Trial Identifiers

Eligibility Criteria:

Gender All	Age >=60 Years	Healthy Volunteers No
----------------------	--------------------------	---------------------------------
